`Earliest priority date
`
`March 16, 2000
`
`REPRESENTATIVE CLINICAL TRIALS OF
`IMMUNOCONJUGATES AS ANTI-SOLID TUMOR AGENTS
`
`Phase II clinical trial of
`Xomazyme-Mel for Metastic
`Melanoma17
`Phase I clinical trial of KSI/4-
`methotrexate for NSCLC18
`KSI/4-Vinca alkaloid conjugate
`clinical study for adenomas19
`Phase I clinical trial of 454A12-
`rRA in ovarian, mesothelial, renal,
`and gastrointestinal cancers20
`
`1992
`
`Chari 1992
`(Ex. 1012)
`
`Phase I/II study of Anti-CEA-
`bR on hepatic metastases of
`gastrointestinal origin24
`
`Phase I trial of LMB-1 in
`patients with advanced
`solid tumors27
`
`Phase I study of hCTM01-
`calicheamicin in epithelial
`ovarian cancer29
`
`Clinical studies of KS1/4-
`Methotrexate in NSCLC25
`
`Phase I/II study of
`XomaZyme-Mel plus
`Cyclosporine A in metastatic
`melanoma23
`
`Phase I trial of XMMCO-791/
`RTA in metastatic
`colon cancer26
`
`Phase I trial of 454 A12-rRA
`in leptomeningeal
`neoplasia28
`
`Phase I trial of ERB-38 (anti-
`erbB2 antibody fused to PE 38) in
`breast and esophageal cancers30
`BR96 – doxorubicin clinical study
`for metastatic cancer31
`
`Study of antibody conjugates
`of daunorubicin and
`chlorambucil in
`neuroblastoma2
`
`Study of a vindesine-anti-
`CEA conjugate in refractory
`advanced metastatic
`adenocarcinomas1
`
`Phase II clinical trial of
`Xomazyme-Mel for Stage III
`Metastatic Melanoma4
`Clinical study of Adriamycin-Ab
`in breast, tongue, lung, and
`colon cancers5
`Clinical study of A7-Mitomycin
`C and A7-neocarzinostatin in
`colorectal cancer6
`Clinical studies of adriamycin,
`idarubicin, chlorambucil,
`melphalan, aminopterin, and
`methotrexate
`immunoconujgates in colorectal
`cancer7
`
`Clinical trial of OVB3-PE for
`refractory ovarian cancer21
`Phase I trial of XomaZyme-
`Mel in metastatic
`melanoma22
`
`1. Ford 1983 (Ex. 2297)
`2. Melino 1984 (Ex. 2302)
`3. Spitler 1987 (Ex. 2193)
`4. Spitler 1988 (Ex. 2313)
`5. Oldham 1988 (Ex. 2304)
`6. Takahashi 1988 (Ex. 2314)
`7. Pietersz 1988 (Ex. 2329)
`8. Weiner 1989, Gould 1989 (Ex. 2162 and 2031)
`9. Byers 1989 (Ex. 2294)
`10. Salem 1989 (Ex. 2309)
`11. Durrant 1989 (Ex. 2328)
`12. Tjandra 1989 (Ex. 2315)
`13. Orr 1989 (Ex. 2307)
`14. Schneck 1989 (Ex. 2311)
`15. Oldham 1989 (Ex. 2305)
`16. Pietersz 1989 (Ex. 2327)
`
`17. Oratz 1990 (Ex. 2306)
`18. Elias 1990 (Ex. 2296)
`19. Schneck 1990 (Ex. 2310)
`20. Bookman 1990 (Ex. 2293)
`21. Pai 1991 (Ex. 2030)
`22. Gonzalez 1991 (Ex. 2299)
`23. Selvaggi 1993 (Ex. 2312)
`24. Zalcberg 1994 (Ex. 2316)
`25. Elias 1994 (Ex. 2011)
`26. LoRusso 1995 (Ex. 2301)
`27. Pai 1996 (Ex. 2308)
`28. Laske 1997 (Ex. 2300)
`29. Gillespie 1998 (Ex. 2298)
`30. Pai-Scherf 1999 (Ex. 2029)
`31. Tolcher 1999 (Ex. 2010)
`
`Phase I clinical trial of
`Xomazyme-Mel for
`Metastatic Melanoma3
`
`Phase I studies of 260F9-ricin
`toxin A-chain for metastatic breast
`carcinoma8
`Phase I trial of XomaZyme-791 in
`metastatic colon cancer9
`Phase I study of Xomazyme-Mel in
`advanced malignant melanoma10
`Phase I trial of XMMCO-791-RTA
`in colorectal cancer11
`Phase I trial of NAcMEL-anti-colon
`cancer MoAbs in advanced
`colorectal carcinoma12
`Phase I trial of Mitomycin Ab
`conjugate in various solid tumors13
`Phase I clinical trial of KSI/4-Vinca
`alkaloid for adenomas14
`Trial of Adriamycin- and
`mitomycin-c-antibody conjugates
`in various disseminated refractory
`malignancies15
`Phase I clinical trial of NAcMEL-
`MoAb immunoconjugates with
`TNF-a in advanced colorectal
`cancer16
`
`IMMUNOGENT 2062, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`